摘要
目的探讨应用血栓通注射液辅助治疗急性脑梗死患者的临床疗效及安全性。方法选取2018年12月至2020年12月江阴市第五人民医院诊治的60例急性脑梗死患者进行前瞻性研究,采用系统抽样法分为研究组和对照组,每组各30例。对照组患者采用常规治疗,研究组患者采用常规治疗辅助血栓通注射液治疗,对比两组患者美国国立卫生研究院卒中量表(NIHSS)评分、临床疗效、炎性因子水平、不良反应发生情况。结果治疗7、14 d后,研究组患者的NIHSS评分比对照组更低(P<0.05);研究组患者比对照组患者的治疗总有效率更高(P<0.05);治疗前两组患者炎性因子水平对比差异无统计学意义(P>0.05),经治疗后研究组患者较对照组血清超敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)指标水平均更低(P<0.05);两组患者不良反应发生情况对比,差异无统计学意义(P>0.05),两组患者的不良反应经治疗后均消失。结论对于急性脑梗死患者应用血栓通注射液治疗,疗效确切,有助于改善患者神经功能缺损,降低血清炎症因子水平,从而改善患者预后。
Objective To investigate the clinical effectiveness and safety of Xueshuantong injection in adjuvant therapy for patients with acute cerebral infarction.Methods 60 patients with acute cerebral infarction admitted to the Jiangyin Fifth People's Hospital from December 2018 to December 2020 were selected as the observation objects,and divided into two groups using systematic sampling method,with 30 patients in each group.The control group was treated with conventional treatment,while the research group was treated with conventional treatment assisted by Xueshuantong injection.The NIHSS scores,clinical efficacy,inflammatory factor levels and incidence of adverse reactions were compared between the two groups.Results NIHSS scores in the research group were significantly lower than those in the control group after 7 and 14 d of treatment(P<0.05).The total effective rate of the research group was higher than that of the control group(P<0.05).Before treatment,there was no significant difference in the levels of inflammatory factors between the two groups(P>0.05).After treatment,the levels of serum hypersensitive C-reactive protein(hs-CRP),IL-6(interleukin-6)and TNF-α(Tumor Necrosis Factor-α)in the research group were lower than those in the control group(P<0.05).There was no significant difference in the rate of incidence of adverse reactions between the two groups(P>0.05),and they all disappeared after later treatment.Conclusion For patients with acute cerebral infarction,Xueshuantong injection has a definite curative effect,which helps to improve patients'neurological deficits,reduce serum inflammatory factor levels and improve patients’prognosis.
作者
陈佳佳
葛海雄
CHEN Jiajia;GE Haixiong(Department of Neurology,Jiangyin Fifth People's Hospital,Wuxi,Jiangsu 214415,China)
出处
《大医生》
2021年第8期14-16,共3页
Doctor
关键词
血栓通注射液
急性脑梗死
炎性因子
Xueshuantong injection
acute cerebral infarction
inflammatory factors
